DIAGNOSTIC TECHNIQUE FOR STOMACH CANCER WITH HER2/NEU OVEREXPRESSION Russian patent published in 2020 - IPC G01N33/48 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and can be used for radionuclide diagnosis of gastric cancer with Her2/neu overexpression. Method involves administering a radiopharmaceutical and performing single-photon emission computed tomography. Radiopharmaceutical used is a radiopharmaceutical based on technetium-99m-labeled recombinant address molecules DARPin9_29, which is prepared immediately before administration according to the developed laboratory regulations: in aseptic conditions 1 ml eluate ^99mTcO^4- 7 GBq is added by syringe into kit for preparation of tricarbonyl technetium and incubated at temperature 100 °C for 30 minutes, after incubation 1000 mcl of technetium tricarbonyl is added to 334 mcl of DARPin9_29 with concentration of basic substance solution of 3.6 mg/l and incubated at temperature of 40 °C for 60 minutes, method includes purifying the obtained compound from protein impurities and non-technetium-bound DARPin9_29 molecules using purification columns, preparation obtained after purification is 500 MBq diluted in 10 ml of normal saline and slowly introduced into a patient through a sterilizing filter. Examination is performed 2 hours after the intravenous introduction; the obtained images are subjected to post-processing treatment and if the accumulation of the preparation increases in the projection of the stomach more than 8 times in relation to the "background" area, a hereditary cancer of Her2/neu expressing expression is diagnosed.

EFFECT: use of the invention enables higher specificity and information value, reduced number of complications and more accessible diagnostic technique.

1 cl, 1 dwg, 1 ex